Our goal is to be the leading global biopharmaceutical company focused on women’s health and other endocrine-related disorders. Our experienced team is dedicated to developing innovative therapies in areas of high unmet medical need to improve the lives of the millions of patients suffering from endocrine-related disorders such as uterine fibroids, endometriosis and prostate cancer.
Our lead program is relugolix, a once-daily, orally administered, small molecule investigational drug candidate that has the potential to be best-in-class for the treatment of uterine fibroids and endometriosis, and a potential best- and first-in-class treatment for advanced prostate cancer. To date, relugolix has been evaluated in over 1,300 patients. Results so far from large, randomized Phase 2 clinical trials in patients with uterine fibroids, endometriosis and prostate cancer have successfully demonstrated significant clinical benefit and that relugolix was generally well-tolerated.
In addition, we are developing MVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility. We believe it has the potential to be a safer alternative to human chorionic gonadotropin as part of assisted reproduction.
Over time, we intend to expand our development pipeline to include other potential treatments for endocrine-related disorders.